6-溴-5-氟-3,4-二氢萘-1(2H)-酮 | 1260013-62-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 6-溴-5-氟-3,4-二氢萘-1(2H)-酮
• 英文名称: 6-bromo-5-fluoro-3,4-dihydronaphthalene-1(2H)-one
• 英文别名: 6-bromo-5-fluoro-3,4-dihydronaphthalen-1(2H)-one；6-bromo-5-fluoro-3,4-dihydro-2H-naphthalen-1-one
• CAS: 1260013-62-4
• 化学式: C₁₀H₈BrFO
• 分子量: 243.075
• InChiKey: ZRBJQOYJAVKRFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-溴-5-氟-3,4-二氢萘-1(2H)-酮 在 盐酸羟胺 作用下， 以 四氢呋喃 为溶剂， 生成 7-bromo-6-fluoro-1,3,4,5-tetrahydro-2H-benzo[b]azepin-2-one
  参考文献：
  名称：

  Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys

  摘要：

  Synthesis and SAR studies of novel triazolobenzazepinones as gamma secretase modulators (GSMs) are presented in this communication. Starting from our azepinone leads, optimization studies toward improving central lowering of A beta 42 led to the discovery of novel benzo-fused azepinones. Several benzazepinones were profiled in vivo and found to lower brain A beta 42 levels in Sprague Dawley rats and transgenic APP-YAC mice in a dose-dependent manner after a single oral dose. Compound 34 was further progressed into a pilot study in our cisterna-magna-ported rhesus monkey model, where we observed robust lowering of CSF A beta 42 levels. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.07.003

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：Bacon Elizabeth M.

  公开号：US20140018313A1

  公开（公告）日：2014-01-16

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及抗病毒化合物、含有这种化合物的组合物、包括给予这种化合物的治疗方法，以及用于制备这种化合物的有用过程和中间体。
• Antiviral compounds
  申请人：GILEAD PHARMASSET LLC

  公开号：US10344019B2

  公开（公告）日：2019-07-09

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及抗病毒化合物、含有此类化合物的组合物、包括施用此类化合物的治疗方法，以及制备此类化合物的工艺和中间体。
• US9156823B2
  申请人：——

  公开号：US9156823B2

  公开（公告）日：2015-10-13
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2012068234A2

  公开（公告）日：2012-05-24

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
• Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys
  作者：Christian Fischer、Susan L. Zultanski、Hua Zhou、Joey L. Methot、Sanjiv Shah、Ikuo Hayashi、Bethany L. Hughes、Christopher M. Moxham、Nathan W. Bays、Nadya Smotrov、Armetta D. Hill、Bo-Sheng Pan、Zhenhua Wu、Lily Y. Moy、Flobert Tanga、Candia Kenific、Jonathan C. Cruz、Deborah Walker、Melanie Bouthillette、George N. Nikov、Sujal V. Deshmukh、Valentina V. Jeliazkova-Mecheva、Damaris Diaz、Maria S. Michener、Jacquelynn J. Cook、Benito Munoz、Mark S. Shearman

  DOI：10.1016/j.bmcl.2015.07.003

  日期：2015.9

  Synthesis and SAR studies of novel triazolobenzazepinones as gamma secretase modulators (GSMs) are presented in this communication. Starting from our azepinone leads, optimization studies toward improving central lowering of A beta 42 led to the discovery of novel benzo-fused azepinones. Several benzazepinones were profiled in vivo and found to lower brain A beta 42 levels in Sprague Dawley rats and transgenic APP-YAC mice in a dose-dependent manner after a single oral dose. Compound 34 was further progressed into a pilot study in our cisterna-magna-ported rhesus monkey model, where we observed robust lowering of CSF A beta 42 levels. (C) 2015 Elsevier Ltd. All rights reserved.